Company Profile
Repligen Stock Price, News & Analysis
- Ticker:
- RGEN
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
159.44 USD (+0.54%)
Close
Last updated: August 6, 2026
6.83B USD
Market cap
Why the stock is moving
As of Aug 6, 2026, RGEN closed up 0.54% at $159.44. No new same-company headline was identified in the current news window.
Company overview
Bioprocessing Technology Supplier
Repligen is a global life sciences company focused on technologies and systems used in biologic drug manufacturing. Its customers include biopharmaceutical developers and contract development and manufacturing organizations seeking greater efficiency, control, and scalability in production.
Four Core Technology Areas
The company’s portfolio spans Filtration and Fluid Management, Chromatography, Process Analytics, and Proteins. Together, these technologies address critical steps from upstream through downstream biologic manufacturing.
Consumables and Workflow Integration
Many Repligen products are recurring-use consumables embedded in validated manufacturing processes. This creates durable customer relationships and demand linked to biologic production volumes, process intensification, and capacity expansion.
Biopharma and CDMO Customer Base
Repligen sells to biologic drug developers, commercial manufacturers, and contract development and manufacturing organizations. Its products can be adopted during process development and remain in use as a therapy advances toward larger-scale and commercial production.
Cell Therapy Supply Chain Expansion
Repligen’s planned acquisition of BioLife Solutions is intended to broaden its consumables and systems presence across cell therapy workflows. The transaction represents an expansion of the company’s manufacturing platform and supply-chain capabilities rather than a single-asset development event.
Future catalysts
Repligen’s watchpoints are bioprocess order recovery, new consumable adoption, and any sign that capital spending is loosening. The key question is whether the update shows enough repeatable demand to look like a durable revenue driver rather than a one-quarter bump. If adoption broadens, sentiment can improve faster than the reported numbers alone would suggest.
Recent news
- 01
- 02
- 03
Repligen to Report Second Quarter 2026 Financial Results
Source: Repligen
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Repligen (RGEN)?
Repligen (RGEN) most recently closed at 159.44 USD, a +0.54% move versus the previous session.
What is the market cap of Repligen (RGEN)?
Repligen currently has a market capitalization of 6.83B USD on BioPharmSignal.
What does Repligen do?
Bioprocessing Technology Supplier Repligen is a global life sciences company focused on technologies and systems used in biologic drug manufacturing. Its customers include biopharmaceutical developers and contract development and manufacturing organizations seeking greater efficiency, control, and scalability in production. Four Core Technology Areas The...
On which exchange is RGEN stock listed?
Repligen (RGEN) is associated with NASDAQ, United States, Biopharma.
What is Bioprocessing?
Bioprocessing Technology Supplier Repligen is a global life sciences company focused on technologies and systems used in biologic drug manufacturing.
Which conditions is Repligen targeting with Bioprocessing?
Bioprocessing Technology Supplier Repligen is a global life sciences company focused on technologies and systems used in biologic drug manufacturing. Its customers include biopharmaceutical developers and contract development and manufacturing organizations seeking greater efficiency, control, and scalability in production. Four Core Technology Areas The...
How does Repligen describe recent progress with Bioprocessing?
Repligen’s watchpoints are bioprocess order recovery, new consumable adoption, and any sign that capital spending is loosening. The key question is whether the update shows enough repeatable demand to look like a durable revenue driver rather than a one-quarter bump. If adoption broadens, sentiment can improve faster than the reported numbers alone would...
What is Technology?
Bioprocessing Technology Supplier Repligen is a global life sciences company focused on technologies and systems used in biologic drug manufacturing.